Posts by Sandra Ansanay-Alex
Using proteins as barcodes to fight against counterfeiting
Nanodecoder, an EPFL spin-off, receives CHF 100 000 from FIT The Fondation pour l’Innovation Technologique selection committee announced they have made an Innogrant award of CHF 100 000 to NanoDecoder – an EPFL-based project developing nanopore sensing technologies to fight conterfeiting and perform molecular diagnostics. The startup is working on engineered bio-nanopore providing fast…
Read MoreNestlé Health Science invests EUR 40 million in Enterome
Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…
Read MoreNestlé Health Science and Perseo Pharma partners to fight digestive diseases
Strategic collaboration to create therapies against digestive diseases Perseo pharma, a preclinical stage biopharmaceutical company focused on breaking new ground in enzyme therapies, has entered a strategic research and development collaboration with Nestlé Health Science S.A. to develop up to three programs targeting enzyme deficiencies in patients suffering from digestive diseases. “We are incredibly…
Read MoreADC Therapeutics signs multi-million dollar licensing agreement with Sobi
The swiss and the Swedish companies partner for the development and commercialization of ZYNLONTA®, a drug for hematologic and solid tumors ADC Therapeutics SA has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the…
Read MoreGnubiotics gets a CHF 1.4 million Innosuisse Grant
The biotech company evaluates the effects of glycopeptides on solid tumors Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides based in Biopôle, announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a…
Read MoreCHF 4 million for b-rayZ AG, a startup fighting breast cancer
The Tech4Eva alumni and University Hospital Zurich (USZ) uses AI for faster and better breast cancer diagnostics b-RayZ AG has closed an oversubscribed Series A financing round worth over four million Swiss francs with leading investors in the Life Sciences and IT sector. The financing round was led by LifeCare Partners, Protagon AG and…
Read MoreKBI Biopharma SA and Selexis SA inaugurated a new facility in Geneva
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, have inaugurated an expanded, fully-integrated mammalian contract development and manufacturing services facility in Plan-les-Ouates in Geneva, Switzerland. The ~8 700 m2 integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell…
Read MoreScaling Up Sales
From the idea to the market, grow your business with a marketing and sales programme Scaling Up Sales is a program supported by the Service de la promotion de l’économie et de l’innovation (SPEI) of the Canton of Vaud, in partnership with Innovaud and the Fondation pour l’Innovation Technologique (FIT). This program supports SMEs…
Read MoreThe canton of Vaud keeps on backing the FIT
The State of Vaud commits on giving CHF 2 million / year to the Fondation pour l’Innovation Technologique (FIT) This is excellent news for the world of innovation in Western Switzerland. The canton of Vaud announced the renewal of its financial contribution to the Fondation pour l’Innovation Technologique to the extent of CHF 16…
Read MoreLonza opens a new production facility in Stein (CH)
Lonza plans to construct a large-scale commercial drug product fill and finish facility in Stein (CH). CHF 500 million will be invested and the plant is expected to be completed in 2026. “This strategic investment completes our offering in drug product and strengthens our position as a leading CDMO with an unparalleled breadth of offerings across…
Read More